Home » Newsletters » BioWorld Science

BioWorld Science

March 1, 2000

View Archived Issues

Cytoclonal isolates new class of genes involved in paclitaxel synthesis

Thai Remune study results reported

Progen uses Australian placement to advance development of PI-88

Cellegy advances transdermal therapies

Role of dietary factors discussed at cardiovascular disease conference

Maxia presents preclinical data for novel insulin sensitizer

GVAX lung cancer vaccine advances to multicenter phase I/II trials

Company Profile: Novirio

Rotamase inhibitors developed at Agouron for neurological disorders

Fujisawa presents new imidazoles with inhibitory activity against adenosine deaminase

New Zambon macrolide with prolonged therapeutic efficacy

Merck patents new series of cytokine inhibitors with imidazole structure

Agents for MTP- and ApoB-dependent conditions presented by Novartis scientists

Deuteroporphyrin-based MRI contrast agents designed at Schering

Ono-2506 has protective and therapeutic efficacy in EAN

Fujisawa backs Adherex and its novel cancer therapeutic

Celgene accelerates development of second-generation compounds from the thalidomide class

Phase I results support further evaluation of i.v. R-101933 + paclitaxel

Periostat receives U.K. marketing approval for treatment of chronic adult periodontitis

FDA approves new Allegra formulations

Santen seeks FDA approval of levofloxacin for bacterial conjunctivitis

RCT forms new bioventure to support biomedical, life sciences discoveries in U.K. and Ireland

Agents for the treatment, prevention and diagnosis of bone disease available for licensing from Salk

Alimta, a multitargeted antifolate: clinical experience outlined at ICACT

AstraZeneca files sNDA with FDA for Casodex 150 mg

Nabi-NicVAX attenuates nicotine dependence in rats

NK1 receptor antagonist and prodrug thereof for treatment of emesis